| 1365 |
National Cancer Institute |
Html |
en |
Treatment-Related Nausea and Vomiting (PDQ®)–Health Professional Version |
Expert-reviewed information summary about nausea and vomiting as complications of cancer or its treatment. Approaches to the management of nausea and vomiting are discussed. |
| Navari RM | 0.607101 |
| emetogenic cancer chemotherapy | 0.63983 |
| Eur J Cancer | 0.609061 |
| delayed chemotherapy-induced nausea | 0.625115 |
| prevention | 0.607994 |
| vomiting | 0.735606 |
| moderately emetogenic cancer | 0.588642 |
| Hesketh PJ | 0.626918 |
| chemotherapy-induced nausea | 0.995758 |
| patients | 0.657649 |
| postchemotherapy nausea | 0.593584 |
| Ann Oncol | 0.583271 |
| future chemotherapy cycles | 0.584523 |
| cancer chemotherapy | 0.674463 |
| postchemotherapy nausea interrelate | 0.583875 |
| Cancer Treat Rep | 0.590867 |
| receptor antagonist | 0.645678 |
| et al. | 0.731812 |
| multiday chemotherapy regimen. | 0.581142 |
| study | 0.614153 |
| 3-day chemotherapy regimens | 0.58215 |
| emetogenic chemotherapy-induced nausea | 0.655987 |
| high-dose cisplatin chemotherapy | 0.594488 |
| highly emetogenic chemotherapy | 0.717945 |
|
| cisplatin chemotherapy | 0.641758 |
| delayed cisplatin-induced nausea | 0.593234 |
| PUBMED Abstract | 0.729569 |
| moderately emetogenic chemotherapy | 0.836636 |
| Support Care Cancer | 0.895503 |
| emetogenic cisplatin-based chemotherapy | 0.601411 |
| emetogenic multi-day chemotherapy | 0.600149 |
| Patients Receiving Chemotherapy | 0.603022 |
| lung cancer chemotherapy | 0.587479 |
| multiday chemotherapy | 0.602924 |
| dexamethasone | 0.645924 |
| Abstract | 0.798738 |
| cisplatin-induced emesis | 0.607512 |
| Clin Oncol | 0.771609 |
| multiday chemotherapy regimen | 0.588792 |
| chemotherapy regimen | 0.594004 |
| multiple-day cisplatin chemotherapy | 0.590292 |
| antiemetic therapy | 0.590387 |
| emetogenic multiple-day chemotherapy | 0.598957 |
| antiemetic efficacy | 0.593069 |
| acute chemotherapy-induced nausea | 0.663254 |
| breakthrough chemotherapy-induced nausea | 0.630049 |
| acute nausea | 0.588031 |
| cisplatin combination chemotherapy | 0.606904 |
|
CLICK HERE |
| 1588 |
National Cancer Institute |
Html |
en |
Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of childhood soft tissue sarcomas. |
| Plexiform fibrohistiocytic tumor | 0.280012 |
| malignant tumor cells | 0.307621 |
| cancer treatment | 0.290865 |
| soft tissue cell | 0.275637 |
| rare tumor | 0.289328 |
| Inflammatory myofibroblastic tumor | 0.282045 |
| childhood soft tissue | 0.441268 |
| cell tumor | 0.287204 |
| body | 0.349975 |
| type | 0.32132 |
| PDQ cancer information | 0.285649 |
| children | 0.277658 |
| clinical trials | 0.413146 |
| clinical trial | 0.299958 |
| clear cell sarcoma | 0.298146 |
| Malignant triton tumor | 0.279981 |
| blood vessels | 0.296075 |
| smooth muscle tumor | 0.277296 |
| lymph nodes | 0.29136 |
| radiation therapy | 0.449797 |
| soft tissue sarcoma | 0.971932 |
| cartilage tumor | 0.284625 |
| treatment | 0.443484 |
| synovial sarcoma | 0.284633 |
|
| Primitive neuroectodermal tumor | 0.276261 |
| nerve sheath tumor | 0.323482 |
| chromosome switches places | 0.389422 |
| cancer cells | 0.417787 |
| tumor cells | 0.415668 |
| tumor suppressor gene | 0.277153 |
| genetic change | 0.398935 |
| soft tissue sarcomas | 0.289965 |
| /extraskeletal Ewing tumor | 0.27615 |
| fibrous tissue tumor | 0.342556 |
| tissue sarcoma cells | 0.300511 |
| primary tumor | 0.287542 |
| metastatic tumor | 0.275814 |
| following types | 0.304501 |
| soft tissue tumors | 0.283665 |
| PDQ summary | 0.323186 |
| tumors | 0.289287 |
| tumor | 0.552574 |
| Tissue Sarcoma Treatment | 0.342732 |
| certain genetic change | 0.378247 |
| cancer | 0.496155 |
| information | 0.290056 |
| Adult Soft Tissue | 0.29745 |
| fast-growing tumor | 0.287416 |
|
CLICK HERE |
| 1642 |
National Cancer Institute |
Html |
en |
714-X (PDQ®)–Patient Version |
714-X is made by mixing chemicals with camphor, a natural substance that comes from the wood and bark of the camphor tree. Read about the theory behind using 714-X and its current use in cancer patients. |
| peer-reviewed scientific journals | 0.537641 |
| treatment | 0.534968 |
| cancer treatment | 0.501509 |
| cancer prevention | 0.385702 |
| Information Service 1-800-4-CANCER | 0.351897 |
| Complementary Therapies Editorial | 0.514523 |
| United States | 0.392202 |
| Cancer Information Specialist | 0.412867 |
| Drug Administration | 0.382831 |
| NCI Best Case | 0.355021 |
| Cancer Information Service | 0.561203 |
| PDQ cancer information | 0.744788 |
| Cancer Complementary | 0.449411 |
| CAM therapies | 0.422313 |
| treatment clinical trials | 0.37249 |
| National Cancer Institute | 0.876336 |
| clinical trials | 0.717035 |
| alternative medicine | 0.550954 |
| health care | 0.367057 |
| scientific journals | 0.644656 |
| cancer information summary | 0.608674 |
| alternative cancer therapies | 0.435258 |
| Federal Trade Commission | 0.400026 |
| National Institutes | 0.384082 |
|
| clinical trial | 0.420566 |
| National Center | 0.380596 |
| CAM cancer research | 0.409541 |
| new treatment | 0.361031 |
| breast cancer prevention | 0.380639 |
| PDQ 714-X | 0.397489 |
| PDQ summaries | 0.352729 |
| cancer patients | 0.471011 |
| Cancer Care page | 0.383195 |
| latest published information | 0.365664 |
| NCI’s PDQ | 0.390788 |
| PDQ summary | 0.383221 |
| Integrative Health | 0.378723 |
| NCI PDQ cancer | 0.513504 |
| cancer information database | 0.431786 |
| alternative therapies | 0.488998 |
| cancer information summaries | 0.432385 |
| Therapies Editorial Board | 0.457631 |
| cancer | 0.995087 |
| research studies | 0.395284 |
| 714-X | 0.480793 |
| fight cancer cells | 0.39917 |
| PDQ Integrative | 0.349747 |
|
CLICK HERE |
| 1662 |
National Cancer Institute |
Html |
en |
Childhood Craniopharyngioma Treatment (PDQ®)–Patient Version |
Childhood craniopharyngiomas are benign (not cancer) brain tumors found near the pituitary gland. Learn about the signs, tests to diagnose, and treatment (surgery, radiation therapy, chemotherapy, and immunotherapy) of pediatric craniopharyngioma in this expert-reviewed summary. |
| cancer treatment | 0.48468 |
| biologic therapy | 0.507196 |
| metastatic brain tumors | 0.486695 |
| ongoing clinical trials | 0.484802 |
| type | 0.50142 |
| PDQ cancer information | 0.574719 |
| clinical trial search | 0.540589 |
| brain tumors | 0.522888 |
| clinical trials | 0.951944 |
| Tumors Treatment Overview | 0.504097 |
| Pediatric Treatment Editorial | 0.495313 |
| cancer information summary | 0.533129 |
| External-beam radiation therapy | 0.488413 |
| clinical trial | 0.688299 |
| treatment clinical trial | 0.507181 |
| NCI PDQ cancer | 0.492501 |
| radiation therapy | 0.972274 |
| Treatment Editorial Board | 0.499227 |
| 3-dimensional radiation therapy | 0.515967 |
| late effects | 0.510845 |
| currently used treatment | 0.491406 |
| treatment | 0.796928 |
| PDQ treatment summary | 0.532401 |
| pituitary gland | 0.574023 |
| primary brain tumors | 0.487104 |
|
| PDQ Pediatric Treatment | 0.494857 |
| childhood craniopharyngioma | 0.61051 |
| Benign brain tumors | 0.485617 |
| treatment clinical trials | 0.53534 |
| National Cancer Institute | 0.529019 |
| tumor cells | 0.70293 |
| spinal cord | 0.496884 |
| tumor treatment | 0.551247 |
| optic nerves | 0.511248 |
| Childhood Craniopharyngioma Treatment | 0.498434 |
| new treatment | 0.547603 |
| external radiation therapy | 0.527756 |
| brain | 0.588207 |
| PDQ summary | 0.519792 |
| effects tumor treatment | 0.543564 |
| Intracavitary radiation therapy | 0.548993 |
| radiation treatment | 0.484529 |
| cancer clinical trials | 0.558097 |
| tumor | 0.711831 |
| treatment options | 0.489122 |
| internal radiation therapy | 0.557881 |
| cancer | 0.593059 |
| standard treatment | 0.499934 |
| spinal cord tumors | 0.49494 |
|
CLICK HERE |
| 1748 |
National Cancer Institute |
Html |
en |
Formaldehyde and Cancer Risk |
A fact sheet that discusses formaldehyde and its possible association with cancer. Includes resources for more information. |
| U.S. Consumer Product | 0.507182 |
| potential health effects | 0.45175 |
| nasopharyngeal cancer | 0.446819 |
| formaldehyde resins | 0.646729 |
| paper product coatings | 0.444118 |
| formaldehyde exposure | 0.974129 |
| cumulative exposure | 0.471192 |
| case-control studies | 0.464784 |
| health care professionals | 0.44942 |
| laboratory studies | 0.445025 |
| building materials | 0.458544 |
| highest estimated formaldehyde | 0.647871 |
| formaldehyde exposure limit | 0.684002 |
| long-term health effects | 0.450096 |
| probable human carcinogen | 0.44463 |
| formaldehyde exposure levels | 0.675206 |
| industrial workers | 0.445134 |
| short-term health effects | 0.476808 |
| Environmental Protection Agency | 0.476151 |
| workplace exposure | 0.472844 |
| myeloid leukemia | 0.515754 |
| high formaldehyde levels | 0.685556 |
| pressed-wood products | 0.507453 |
| occupational formaldehyde exposure | 0.700409 |
|
| Product Safety Commission | 0.506904 |
| cohort study | 0.490021 |
| National Toxicology Program | 0.502466 |
| household products | 0.463834 |
| British industry workers | 0.444394 |
| U.S. Environmental Protection | 0.477699 |
| occupational exposure | 0.487391 |
| Occupational Safety | 0.475151 |
| Emergency Management Agency | 0.463126 |
| human carcinogen | 0.45778 |
| National Cancer Institute | 0.452741 |
| lymphatic systems | 0.444691 |
| formaldehyde gas | 0.693298 |
| Health Administration | 0.456674 |
| NCI cohort | 0.451429 |
| NCI case-control study | 0.460446 |
| occupational exposure limits | 0.480797 |
| Consumer Product Safety | 0.50691 |
| NCI industrial cohort | 0.459283 |
| lung cancer deaths | 0.469841 |
| funeral industry workers | 0.472946 |
| lung cancer mortality | 0.44468 |
| formaldehyde content | 0.617511 |
| prolonged exposure | 0.474993 |
|
CLICK HERE |
| 1756 |
National Cancer Institute |
Html |
en |
Alcohol and Cancer Risk |
A fact sheet that summarizes the evidence linking alcohol consumption to the risk of various cancers. Includes information about factors that affect the risk of alcohol-associated cancers. |
| major risk factor | 0.235988 |
| esophageal cancer | 0.270931 |
| alcohol content | 0.304765 |
| alcohol-associated cancer risk | 0.218724 |
| alcohol dehydrogenase | 0.277499 |
| Heavy alcohol | 0.291007 |
| alcohol consumption | 0.743494 |
| modestly increased risk | 0.222903 |
| colorectal cancer risk | 0.261495 |
| alcohol drinkers | 0.284781 |
| drinking alcohol | 0.321106 |
| alcohol intake | 0.325944 |
| ethyl alcohol | 0.305684 |
| percent alcohol | 0.349039 |
| moderate alcohol drinking | 0.333262 |
| Alcohol Abuse | 0.303318 |
| studies | 0.234236 |
| cancer risk declines | 0.219417 |
| alcohol | 0.928418 |
| pure alcohol | 0.321046 |
|
| Moderate alcohol intake | 0.283695 |
| esophageal squamous cell | 0.212278 |
| breast cancer risk | 0.237174 |
| S. Alcohol drinking | 0.301428 |
| alcohol-related esophageal cancer | 0.211228 |
| breast cancer | 0.381145 |
| alcohol drinking | 0.503002 |
| neck cancers | 0.250896 |
| pancreatic cancer risk | 0.215956 |
| neck cancer | 0.200912 |
| regular alcohol consumption | 0.359735 |
| et al | 0.397799 |
| cancer risk | 0.361737 |
| cancers | 0.264383 |
| oral cavity | 0.23106 |
| cancer | 0.549181 |
| risk | 0.431925 |
| liver cancer | 0.219113 |
| enzyme drink alcohol | 0.313977 |
|
CLICK HERE |
| 2016 |
National Cancer Institute |
Html |
es |
Aspectos generales de la prevención del cáncer (PDQ®)–Versión para pacientes |
Información general sobre la prevención del cáncer y descripciones de conceptos usados en sumarios específicos sobre la prevención del cáncer. |
| radiación ionizante causa | 0.460647 |
| cientÃficos estudian | 0.489171 |
| Vitamina B12 | 0.441748 |
| principales factores | 0.444309 |
| altos costos | 0.431231 |
| siguientes tipos | 0.443767 |
| Vitamina C | 0.440272 |
| determinadas sustancias | 0.434346 |
| bacteria helicobacter | 0.42962 |
| Vitamina B6 | 0.441932 |
| Clinical Trials Registry | 0.438953 |
| vitamina d | 0.4813 |
| National Cancer Institute | 0.429703 |
| siguientes riesgos | 0.428971 |
| alto contenido | 0.463103 |
| ligera disminución | 0.41989 |
| vitamina e | 0.538039 |
| Instituto Nacional | 0.447408 |
|
| OmegA-3 TriaL | 0.424385 |
| antecedentes familiares | 0.422212 |
| sumario prevención | 0.489845 |
| Cancer Prevention Trial | 0.437168 |
| hepatitis b | 0.427578 |
| Physician Data Query | 0.503692 |
| células tumorales benignas | 0.462584 |
| Radiación ultravioleta | 0.43604 |
| Leucemia mielógena aguda | 0.449074 |
| Estados Unidos | 0.563042 |
| prevención revisa | 0.457445 |
| Physician´s Health Study | 0.436091 |
| cabo estudios | 0.425211 |
| PDQ Prevención | 0.699792 |
| siguientes vitaminas | 0.436186 |
| siguientes medicamentos | 0.44035 |
| Gas radón | 0.426739 |
| PDQ Aspectos | 0.466808 |
|
CLICK HERE |
| 16473 |
National Cancer Institute |
Html |
en |
Nivolumab Improves Survival for Patients with Recurrent Head and Neck Cancer |
A summary of clinical trial results showing that nivolumab (Opdivo®) improved overall survival compared with standard chemotherapy in patients with head and neck squamous cell carcinoma. |
| platinum-based chemotherapy | 0.436007 |
| immune checkpoint inhibitor | 0.707571 |
| pembrolizumab block | 0.240544 |
| checkpoint inhibitor nivolumab | 0.489462 |
| standard therapy group | 0.856853 |
| HNSCC tumor growth | 0.401684 |
| squamous cells | 0.272124 |
| Cancer Therapy Evaluation | 0.372634 |
| overall survival | 0.94063 |
| broader group | 0.255871 |
| poor prognoses | 0.250488 |
| median progression-free survival | 0.452131 |
| Pittsburgh Medical Center | 0.399432 |
| Maura L. Gillison | 0.401307 |
| Bristol-Myers Squibb | 0.274378 |
| median overall survival | 0.493854 |
| patients | 0.514717 |
| metastatic HNSCC | 0.274208 |
| HNSCC | 0.412159 |
| effective second-line therapy | 0.394916 |
| Shakun Malik | 0.250672 |
| Drug Administration | 0.252661 |
| cancer cells | 0.262643 |
| treatment-related adverse events | 0.35048 |
|
| Human papillomavirus | 0.256631 |
| better treatment | 0.263098 |
| unacceptable side effects | 0.245803 |
| median follow-up | 0.28334 |
| PD-L1—a molecule | 0.240638 |
| nivolumab group | 0.622355 |
| tumor cells | 0.248287 |
| new trial | 0.243059 |
| standard chemotherapy | 0.417786 |
| Ohio State University | 0.396086 |
| median length | 0.283635 |
| immune cells | 0.271394 |
| salivary glands | 0.258435 |
| nasal passages | 0.247938 |
| Robert L. Ferris | 0.397098 |
| Cancer Institute | 0.278018 |
| neck cancer | 0.259993 |
| tumor response | 0.240293 |
| common adverse events | 0.34039 |
| New England Journal | 0.393835 |
| oral cavity | 0.246829 |
| checkpoint molecule PD-1 | 0.389662 |
| Earlier studies | 0.247274 |
| phase III trial | 0.261728 |
|
CLICK HERE |
| 16718 |
National Cancer Institute |
Html |
es |
Estudios clínicos de cáncer en el Centro Clínico de los Institutos Nacionales de la Salud |
Información acerca de los estudios clínicos de cáncer en el Centro Clínico de NIH en Bethesda, Maryland. |
| Centro ClÃnico | 0.997868 |
| investigación clÃnica | 0.340866 |
|
| Estados Unidos | 0.385246 |
| Institutos Nacionales | 0.316065 |
|
CLICK HERE |
| 16850 |
National Cancer Institute |
Html |
es |
Sulfato de hidracina (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos sobre el uso del sulfato de hidracina como tratamiento para personas con cáncer. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta. |
| cancer treatment | 0.309808 |
| Cancer Res Clin | 0.314959 |
| patients with weight | 0.313024 |
| Bhide SV | 0.308798 |
| Lung tumor induction | 0.305602 |
| Leukemia Group B | 0.306125 |
| Leukemia Group | 0.310364 |
| Toth B | 0.324797 |
| intramuscular carcinoma | 0.305811 |
| Cancer Res | 0.346197 |
| clinical study | 0.310429 |
| clinical trial | 0.304403 |
| Filov VA | 0.304814 |
| Res Clin Oncol | 0.306832 |
| Estados Unidos | 0.307293 |
| Natl Cancer Inst | 0.349481 |
| Kosty MP | 0.307691 |
| repuesta tumoral objetiva | 0.307141 |
| investigational new drug | 0.305732 |
| Danova LA | 0.311765 |
| non-small cell lung | 0.304038 |
| patients with | 0.351997 |
| investigación clÃnica | 0.304586 |
| Gershanovich ML | 0.316882 |
| evaluable patients | 0.305223 |
|
| studies with | 0.304111 |
| Control Clin Trials | 0.304096 |
| new drugs | 0.310502 |
| Regelson W | 0.307129 |
| National Toxicology Program | 0.310712 |
| diagnosed non-small-cell lung | 0.308493 |
| Grosvenor M | 0.308061 |
| Nutr Cancer | 0.31929 |
| clinical study antitumor | 0.304647 |
| Gold J | 0.349764 |
| treatment with | 0.310953 |
| Herndon JE | 0.307454 |
| Cancer Treatment Group | 0.306186 |
| Treat Rep | 0.305235 |
| nutritional status | 0.304262 |
| Invest New Drugs | 0.305807 |
| Clin Oncol | 0.367278 |
| Chlebowski RT | 0.319227 |
| hydrazine sulfate | 0.975261 |
| Bulcavage L | 0.308142 |
| Mutat Res | 0.30448 |
| treated with | 0.304341 |
| lung tumours | 0.306046 |
| treatment with sehydrin | 0.310193 |
|
CLICK HERE |